Bioprocessing Monitoring Market Global Report 2026

The bioprocessing monitoring market size has grown rapidly in recent years. It will grow from $11.55 billion in 2025 to $12.75 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rise in biologics manufacturing demand driving need for process control, increasing regulatory emphasis on gmp compliant production monitoring, expansion of industrial fermentation in pharmaceuticals and food sectors, growing adoption of automated bioreactors in research labs, need for improved batch consistency and yield optimization in traditional bioprocessing.

The bioprocessing monitoring market size is expected to see strong growth in the next few years. It will grow to $18.63 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing demand for personalized biologics and advanced therapeutics production, expansion of cell and gene therapy manufacturing pipelines, rising focus on continuous bioprocessing and real time quality assurance, growing investments in sustainable and efficient biomanufacturing systems, increasing integration of advanced sensor fusion for predictive process control. Major trends in the forecast period include real time bioreactor parameter tracking for improved yield consistency, adoption of advanced process analytical technology (pat) for inline quality assurance in bioprocessing, increasing use of single use sensor based monitoring systems in flexible manufacturing setups, expansion of aseptic monitoring techniques to enhance contamination control in biologics production, growing integration of high resolution spectroscopy based monitoring for enhanced metabolite and nutrient tracking.

The increasing adoption of personalized medicine is expected to propel the growth of the bioprocess monitoring market going forward. Personalized medicine refers to a medical approach that uses individual genetic and personal data to tailor treatment and improve patient outcomes. The increasing adoption of personalized medicine is driven by advancements in genomic sequencing, which enable faster and more affordable analysis of individual genetic profiles for targeted and more effective treatments. Bioprocess monitoring supports personalized medicine by enabling precise control and real-time monitoring of biological production processes, ensuring that patient-specific therapies such as biologics and cell-based treatments are consistently safe, effective, and tailored to individual needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, compared to six in 2022. The personalized treatments approved in 2023 also included seven cancer drugs and three therapies for other diseases and conditions. Therefore, the increasing adoption of personalized medicine is driving the growth of the bioprocess monitoring market.

Leading companies operating in the bioprocess monitoring market are focusing on developing innovative solutions, such as cloud-based bioprocess analytics platforms, to enable real-time process monitoring, centralized data integration, and predictive optimization of biomanufacturing operations. A cloud-based bioprocess analytics platform is a cloud-hosted system that collects and analyzes bioprocess data in real time to improve monitoring, control, and efficiency in biomanufacturing. For example, in July 2024, Eppendorf AG, a Germany-based life science company, launched BioNsight Cloud, a cloud-based digital platform designed to collect, integrate, and analyze bioprocess data in real time from laboratory and biomanufacturing systems. It enables real-time remote process monitoring, multi-user collaboration, and seamless integration with DataHowLab for advanced, AI-driven analytics to accelerate process understanding and optimization.

In March 2025, Repligen Corporation, a US-based life sciences company, acquired the Bioprocessing Analytics Portfolio from 908 Devices Inc. for an undisclosed amount. Through this acquisition, Repligen aimed to strengthen its bioprocessing analytics portfolio by expanding its process analytical technology capabilities for real-time monitoring and optimization of biologics manufacturing. 908 Devices Inc. is a US-based technology company that provides bioprocess monitoring solutions and develops process analytical technology (PAT) solutions.

Major companies operating in the bioprocessing monitoring market are Thermo Fisher Scientific Inc.; Danaher Corporation; Honeywell International Inc.; Emerson Electric Co.; Merck KGaA; Sartorius AG; Agilent Technologies Inc.; Yokogawa Electric Corp.; Waters Corporation; Shimadzu Corporation; Bruker Corporation; Bio-Rad Laboratories Inc.; Endress+Hauser Group Services AG; Repligen Corporation; Eppendorf SE; Nova Biomedical Corporation; Aber Instruments Ltd.; ArgusEye; Adson Biotech; Holloid; Infera; LatchBio.

North America was the largest region in the bioprocessing monitoring market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocessing monitoring market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocessing monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioprocess monitoring market consists of revenues earned by entities by providing services such as data acquisition and process data logging, contamination detection and control monitoring, and bioreactor performance monitoring and optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess monitoring market also includes sales of biomass sensors, carbon dioxide (CO₂) sensors, and flow rate sensors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The bioprocessing monitoring market research report is one of a series of new reports that provides bioprocessing monitoring market statistics, including bioprocessing monitoring industry global market size, regional shares, competitors with a bioprocessing monitoring market share, detailed bioprocessing monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocessing monitoring industry. This bioprocessing monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.